ArticleBMC public health2025
Burdens of sense organ diseases across global, regional, and national levels from 1990 to 2021 and projections for 2050.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hearing Loss as a Potentially Modifiable Marker of Dementia Risk: Neurological Evidence, Uncertainty, and Clinical Interpretation.Neuro-degenerative diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSensory organ diseases (SOD) pose a considerable challenge to global health. This study analyzed the burden of SOD from 1990 to 2021 using data from the Global Burden of Disease (GBD) 2021.
methodsWe analyzed prevalence, disability-adjusted life years (DALYs), and age-standardized rates using Joinpoint regression and age-period-cohort (APC) models to separate the effects of age, period, and birth cohort. Health inequalities were evaluated through the slope index of inequality (SII) and concentration index (CI). Additionally, we identified risk factors influencing DALYs and projected future disease burden trends for 2022 to 2051 using Bayesian age-period-cohort (BAPC) models.
resultsIn 2021, the global prevalent cases of SOD reached 2,386,160,888 (95% uncertainty interval [UI]: 2,207,871,226 to 2,591,000,614), with 77,327,293 DALYs cases (95% UI: 53,419,192 to 107,972,583). Age-related hearing loss was the most common condition, accounting for 1,545,690,283 prevalent cases (95% UI: 1,480,358,023 to 1,618,714,974) and 44,449,944 DALYs cases (95% UI: 30,689,648 to 62,029,878). The highest age-standardized prevalence rates (ASPR) for blindness and vision loss were observed in Southern Sub-Saharan Africa and South Asia. DALYs attributable to high fasting plasma glucose and high body mass index (BMI) increased significantly from 903,991 to 97,878 in 1990 to 1,555,976 and 229,558 in 2021, respectively. Health inequality analysis revealed a reduction in both SII and CI for SOD from 1990 to 2021, indicating an improvement in health inequality. Future projections indicate that from 2022 to 2051, ASPR for SOD will continue to increase, with the ASPR of blindness and vision loss increasing by about 17.78%. While age-standardized DALYs rates (ASDR) are expected to stabilize, with the ASDR of age-related and other hearing losses is expected to rise by approximately 0.67%.
conclusionThe burden of SOD is high and unevenly distributed. Increasing prevalence and DALYs highlight the need for targeted interventions. Future efforts should focus on risk mitigation and reducing health inequalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.